Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Interest Expenses (2017 - 2024)

Neurocrine Biosciences filings provide 8 years of Interest Expenses readings, the most recent being $1.1 million for Q1 2024.

  • On a quarterly basis, Interest Expenses changed 0.0% to $1.1 million in Q1 2024 year-over-year; TTM through Dec 2024 was $1.1 million, a 76.09% decrease, with the full-year FY2023 number at $4.6 million, down 35.21% from a year prior.
  • Interest Expenses hit $1.1 million in Q1 2024 for Neurocrine Biosciences, roughly flat from $1.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $8.5 million in Q3 2020 to a low of $1.1 million in Q4 2022.
  • Median Interest Expenses over the past 5 years was $2.6 million (2022), compared with a mean of $4.2 million.
  • Biggest five-year swings in Interest Expenses: grew 6.25% in 2020 and later plummeted 83.33% in 2022.
  • Neurocrine Biosciences' Interest Expenses stood at $7.8 million in 2020, then decreased by 15.38% to $6.6 million in 2021, then plummeted by 83.33% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024.
  • The last three reported values for Interest Expenses were $1.1 million (Q1 2024), $1.1 million (Q4 2023), and $1.1 million (Q3 2023) per Business Quant data.